References
- Mangat AK, Schmölzer GM, Kraft WK. Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). Semin Fetal Neonatal Med. 2019;24(2):133–41. [accessed 2021 Oct 10]. doi:https://doi.org/10.1016/j.siny.2019.01.009.
- Patrick SW, Barfield WD, Poindexter BB, Committee on Fetus and Newborn, Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. Pediatrics. 2020;146(5):e2020029074. doi:https://doi.org/10.1542/peds.2020-029074.
- Grossman MR, Lipshaw MJ, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. Hosp Pediatr. 2018;8(1):1–6. doi:https://doi.org/10.1542/hpeds.2017-0128.
- Kraft WK, Stover MW, Davis JM. Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Semin Perinatol. 2016;40(3):203–12. doi:https://doi.org/10.1053/j.semperi.2015.12.007.
- Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, Ehrlich ME. Buprenorphine for the treatment of the neonatal abstinence syndrome. N Engl J Med. 2017;376(24):2341–8. doi:https://doi.org/10.1056/NEJMoa1614835.
- Bulbul A, Celiker EY, Calapcikay U, Uslu S. Neonatal abstinence syndrome, and medical social service management. Sisli Etfal. 2017;51(4):266–77. doi:https://doi.org/10.5350/SEMB.20170911063035.
- Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, CARE Group. The CARE guidelines: consensus‐based clinical case reporting guideline development. Glob Adv Health Med. 2013;2(5):38–43. doi:https://doi.org/10.7453/gahmj.2013.008.
- Highlights of prescribing information for SUBUTEX® (buprenorphine sublingual tablets). [accessed 2021 Jul 30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020732s022lbl.pdf.
- American Academy of Pediatrics Committee on Drugs: Naloxone dosage and route of administration for infants and children: addendum to emergency drug doses for infants and children. Pediatrics. 1990;86(3):484–5.
- Highlights of prescribing information for NARCAN® nasal spray. A1135 Issued: 08/2020. https://www.narcan.com/static/Gen2-Prescribing-Information.pdf.
- Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2 Suppl):S39–S47. doi:https://doi.org/10.1016/s0376-8716(03)00058-9.
- Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl). 2001;154(3):230–42. doi:https://doi.org/10.1007/s002130000637.
- Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet. 2004;43(5):329–40. doi:https://doi.org/10.2165/00003088-200443050-00005.
- Highlights of prescribing information for ssSUBOXONE® (buprenorphine and naloxone). [accessed 2021 Jul 30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020733s022lbl.pdf.
- Post S, Spiller HA, Casavant MJ, Chounthirath T, Smith GA. Buprenorphine exposures among children and adolescents reported to US poison control centers. Pediatrics. 2018;142(1):e20173652. doi:https://doi.org/10.1542/peds.2017-3652.
- Jumah NA, Edwards C, Balfour-Boehm J, Loewen K, Dooley J, Gerber Finn L, Kelly L. Observational study of the safety of buprenorphine + naloxone in pregnancy in a rural and remote population. BMJ Open. 2016;6(10):e011774. open-2016-011774 doi:https://doi.org/10.1136/BMJ.
- Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015;125(2):363–8. doi:https://doi.org/10.1097/AOG.0000000000000640.
- Debelak K, Morrone WR, O’Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 2013;22(3):252–4. doi:https://doi.org/10.1111/j.1521-0391.2012.12005.x.
- Wiegand SL, Swortwood MJ, Huestis MA, Thorp J, Jones HE, Vora NL. Naloxone and metabolites quantification vin cord blood of prenatally exposed newborns and correlations with maternal concentrations. AJP Rep. 2016;6(4):e385–90. doi:https://doi.org/10.1055/s-0036-1593993.
- Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 1990;25(1):27–34. doi:https://doi.org/10.1016/0376-8716(90)90136-3.
- Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend. 2007;90(2–3):261–9. doi:https://doi.org/10.1016/j.drugalcdep.2007.04.006.